Cargando…
Investigating the Potential of Conjugated Selenium Redox Folic Acid as a Treatment for Triple Negative Breast Cancer
Previous studies have demonstrated that redox selenium compounds arrest cancer cell viability in vitro through their pro-oxidative activity by generating superoxide (O(2)(•−)). Currently, there are no efficacious treatment options for women with Triple Negative Breast Cancer (TNBC). However, the ass...
Autores principales: | Khandelwal, Soni, Boylan, Mallory, Kirsch, Gilbert, Spallholz, Julian E., Gollahon, Lauren S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071027/ https://www.ncbi.nlm.nih.gov/pubmed/32033374 http://dx.doi.org/10.3390/antiox9020138 |
Ejemplares similares
-
Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells
por: Khandelwal, Soni, et al.
Publicado: (2018) -
Redox-Active Selenium Compounds—From Toxicity and Cell Death to Cancer Treatment
por: Misra, Sougat, et al.
Publicado: (2015) -
Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple-negative breast cancer cells
por: LEE, JAEHYUNG, et al.
Publicado: (2013) -
In Vitro Cytotoxicity of Trastuzumab (Tz) and Se-Trastuzumab (Se-Tz) against the Her/2 Breast Cancer Cell Lines JIMT-1 and BT-474
por: Bapat, Priyanka, et al.
Publicado: (2021) -
Avidity Mechanism of Dendrimer–Folic Acid Conjugates
por: van Dongen, Mallory A., et al.
Publicado: (2014)